Share Price and Basic Stock Data
Last Updated: December 27, 2025, 11:02 pm
| PEG Ratio | -1.44 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Concord Biotech Ltd operates in the pharmaceuticals industry, with its stock price currently at ₹1,340 and a market capitalization of ₹14,024 Cr. The company’s sales have shown a steady upward trajectory, rising from ₹713 Cr in March 2022 to ₹853 Cr in March 2023, and are anticipated to reach ₹1,200 Cr by March 2025. Quarterly revenue trends indicate fluctuations, with the highest sales recorded at ₹319 Cr in March 2024, while the latest quarter, September 2023, reported sales of ₹262 Cr. The operating profit margins (OPM) have remained robust, averaging around 40% in recent quarters, reflecting efficiency in cost management. The company’s ability to maintain a competitive edge in a growing market is underscored by a notable increase in total sales over the years, indicating a strong demand for its products. As the company continues to expand its portfolio and address market needs, it stands poised for sustained growth.
Profitability and Efficiency Metrics
Concord Biotech has demonstrated solid profitability metrics, with a net profit of ₹322 Cr reported for the trailing twelve months and a net profit margin of 31.07% for March 2025. The operating profit for the same period stood at ₹507 Cr, yielding an OPM of 42%. The company’s return on equity (ROE) is impressive at 21.4%, while the return on capital employed (ROCE) is reported at 28.4%, both indicating effective capital utilization. Additionally, the interest coverage ratio is exceptionally high at 1040.58x, suggesting that the company’s earnings comfortably cover its interest obligations. However, the cash conversion cycle (CCC) of 310 days indicates potential inefficiencies in working capital management, as it reflects the time taken to convert investments in inventory and other resources into cash flows from sales. This metric, coupled with a growing inventory turnover ratio of 5.36, highlights the need for continued focus on operational efficiency.
Balance Sheet Strength and Financial Ratios
Concord Biotech’s balance sheet reflects substantial financial strength, with total assets reported at ₹2,034 Cr and negligible borrowings of just ₹2 Cr. The company has built considerable reserves, totaling ₹1,815 Cr, which bolsters its equity base and provides a buffer for future expansion. The current ratio is notably high at 6.17, indicating a robust liquidity position, while the quick ratio of 4.87 further affirms the company’s ability to meet short-term obligations without relying on inventory sales. The price-to-book value (P/BV) ratio currently stands at 9.67x, which may suggest that the stock is trading at a premium compared to its book value, potentially reflecting market confidence in future growth prospects. However, the company’s reliance on internal funding, as indicated by the low debt-to-equity ratio of 0.00, while advantageous, may limit its leverage for aggressive growth strategies.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Concord Biotech reveals a stable ownership structure, with promoters holding 44.08% of the shares, reflecting strong internal confidence in the company. Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) hold 8.03% and 9.55%, respectively, indicating a moderate level of institutional interest. The public holds 38.32%, suggesting a healthy retail investor base with a total of 82,650 shareholders. Over time, FII participation has seen a slight increase, from 7.30% in September 2023 to 9.35% in March 2025, which could signal growing confidence in the company’s long-term growth potential. However, the decline in the number of shareholders from 100,927 in September 2023 to 82,650 in September 2025 raises questions about retail investor sentiment and may warrant further analysis to assess the underlying factors influencing this trend.
Outlook, Risks, and Final Insight
Looking ahead, Concord Biotech is well-positioned to capitalize on growth opportunities within the pharmaceuticals sector, bolstered by its strong revenue growth, profitability metrics, and solid balance sheet. However, the company faces potential risks, including high operational costs associated with maintaining its competitive position and managing its cash conversion cycle effectively. Additionally, the premium valuation reflected in the P/BV ratio may pose challenges if market conditions shift. The company’s focus on innovation and expansion into new markets will be critical in mitigating these risks and sustaining its growth trajectory. Should the company successfully enhance its working capital efficiency and maintain investor confidence, it could further solidify its standing as a leader in the pharmaceutical industry. Overall, while challenges exist, the fundamental strengths present a compelling investment case for those looking at long-term value creation in the sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 99.8 | 231/84.3 | 27.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.54 Cr. | 1.85 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,830 Cr. | 443 | 479/192 | 100 | 24.3 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 36.3 Cr. | 49.0 | 88.6/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 50.6 Cr. | 34.6 | 35.0/17.0 | 120 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,105.46 Cr | 1,149.90 | 52.70 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 159 | 241 | 273 | 195 | 262 | 241 | 319 | 216 | 310 | 244 | 430 | 204 | 247 |
| Expenses | 121 | 129 | 144 | 123 | 143 | 135 | 185 | 135 | 174 | 146 | 239 | 143 | 157 |
| Operating Profit | 38 | 112 | 129 | 72 | 119 | 106 | 134 | 81 | 137 | 98 | 190 | 61 | 91 |
| OPM % | 24% | 46% | 47% | 37% | 45% | 44% | 42% | 38% | 44% | 40% | 44% | 30% | 37% |
| Other Income | 6 | 9 | 12 | 7 | 8 | 8 | 11 | 10 | 10 | 15 | 9 | 14 | 13 |
| Interest | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 13 | 14 | 14 | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 |
| Profit before tax | 30 | 106 | 126 | 65 | 113 | 100 | 131 | 78 | 133 | 99 | 185 | 57 | 86 |
| Tax % | 26% | 26% | 26% | 25% | 25% | 26% | 26% | 25% | 26% | 25% | 23% | 26% | 26% |
| Net Profit | 22 | 79 | 94 | 48 | 84 | 75 | 97 | 58 | 99 | 74 | 142 | 43 | 63 |
| EPS in Rs | 2.14 | 7.56 | 8.94 | 4.63 | 8.08 | 7.13 | 9.29 | 5.57 | 9.43 | 7.08 | 13.57 | 4.07 | 6.01 |
Last Updated: December 27, 2025, 11:33 am
Below is a detailed analysis of the quarterly data for Concord Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 204.00 Cr. (Jun 2025) to 247.00 Cr., marking an increase of 43.00 Cr..
- For Expenses, as of Sep 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 143.00 Cr. (Jun 2025) to 157.00 Cr., marking an increase of 14.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 91.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Jun 2025) to 91.00 Cr., marking an increase of 30.00 Cr..
- For OPM %, as of Sep 2025, the value is 37.00%. The value appears strong and on an upward trend. It has increased from 30.00% (Jun 2025) to 37.00%, marking an increase of 7.00%.
- For Other Income, as of Sep 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 14.00 Cr. (Jun 2025) to 13.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 18.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 18.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 86.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Jun 2025) to 86.00 Cr., marking an increase of 29.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 26.00%.
- For Net Profit, as of Sep 2025, the value is 63.00 Cr.. The value appears strong and on an upward trend. It has increased from 43.00 Cr. (Jun 2025) to 63.00 Cr., marking an increase of 20.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 6.01. The value appears strong and on an upward trend. It has increased from 4.07 (Jun 2025) to 6.01, marking an increase of 1.94.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:56 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 340 | 436 | 512 | 617 | 713 | 853 | 1,017 | 1,200 | 1,125 |
| Expenses | 195 | 256 | 308 | 289 | 439 | 509 | 585 | 693 | 685 |
| Operating Profit | 145 | 180 | 205 | 328 | 274 | 344 | 432 | 507 | 440 |
| OPM % | 43% | 41% | 40% | 53% | 38% | 40% | 42% | 42% | 39% |
| Other Income | 18 | 17 | 31 | 14 | 23 | 35 | 34 | 44 | 51 |
| Interest | 1 | 1 | 1 | 1 | 6 | 5 | 3 | 1 | 0 |
| Depreciation | 18 | 19 | 21 | 28 | 50 | 54 | 54 | 54 | 64 |
| Profit before tax | 144 | 178 | 213 | 313 | 241 | 320 | 409 | 496 | 427 |
| Tax % | 30% | 33% | 21% | 25% | 26% | 26% | 26% | 25% | |
| Net Profit | 100 | 118 | 169 | 235 | 179 | 238 | 305 | 373 | 322 |
| EPS in Rs | 105.66 | 124.48 | 177.65 | 247.44 | 187.76 | 22.76 | 29.13 | 35.65 | 30.73 |
| Dividend Payout % | 0% | 21% | 22% | 0% | 3% | 30% | 30% | 25% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 18.00% | 43.22% | 39.05% | -23.83% | 32.96% | 28.15% | 22.30% |
| Change in YoY Net Profit Growth (%) | 0.00% | 25.22% | -4.17% | -62.88% | 56.79% | -4.81% | -5.86% |
Concord Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
Last Updated: September 5, 2025, 3:01 pm
Balance Sheet
Last Updated: December 4, 2025, 2:40 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 585 | 673 | 761 | 990 | 1,098 | 1,282 | 1,515 | 1,802 | 1,815 |
| Borrowings | 22 | 9 | 52 | 89 | 62 | 32 | 10 | 3 | 2 |
| Other Liabilities | 69 | 72 | 118 | 94 | 144 | 191 | 164 | 219 | 194 |
| Total Liabilities | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 | 2,021 |
| Fixed Assets | 189 | 230 | 240 | 546 | 573 | 593 | 575 | 795 | 790 |
| CWIP | 3 | 19 | 141 | 18 | 74 | 173 | 211 | 51 | 74 |
| Investments | 151 | 229 | 199 | 142 | 74 | 138 | 244 | 335 | 354 |
| Other Assets | 343 | 285 | 361 | 477 | 592 | 611 | 668 | 854 | 804 |
| Total Assets | 685 | 763 | 941 | 1,183 | 1,313 | 1,515 | 1,699 | 2,034 | 2,021 |
Below is a detailed analysis of the balance sheet data for Concord Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,815.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,802.00 Cr. (Mar 2025) to 1,815.00 Cr., marking an increase of 13.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 3.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 194.00 Cr.. The value appears to be improving (decreasing). It has decreased from 219.00 Cr. (Mar 2025) to 194.00 Cr., marking a decrease of 25.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,021.00 Cr.. The value appears to be improving (decreasing). It has decreased from 2,034.00 Cr. (Mar 2025) to 2,021.00 Cr., marking a decrease of 13.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 790.00 Cr.. The value appears to be declining and may need further review. It has decreased from 795.00 Cr. (Mar 2025) to 790.00 Cr., marking a decrease of 5.00 Cr..
- For CWIP, as of Sep 2025, the value is 74.00 Cr.. The value appears strong and on an upward trend. It has increased from 51.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 23.00 Cr..
- For Investments, as of Sep 2025, the value is 354.00 Cr.. The value appears strong and on an upward trend. It has increased from 335.00 Cr. (Mar 2025) to 354.00 Cr., marking an increase of 19.00 Cr..
- For Other Assets, as of Sep 2025, the value is 804.00 Cr.. The value appears to be declining and may need further review. It has decreased from 854.00 Cr. (Mar 2025) to 804.00 Cr., marking a decrease of 50.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,021.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,034.00 Cr. (Mar 2025) to 2,021.00 Cr., marking a decrease of 13.00 Cr..
Notably, the Reserves (1,815.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 123.00 | 171.00 | 153.00 | 239.00 | 212.00 | 312.00 | 422.00 | 504.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 236 | 133 | 131 | 105 | 119 | 117 | 125 | 159 |
| Inventory Days | 381 | 310 | 312 | 503 | 434 | 430 | 331 | 286 |
| Days Payable | 210 | 112 | 201 | 152 | 185 | 190 | 150 | 135 |
| Cash Conversion Cycle | 407 | 331 | 242 | 456 | 368 | 357 | 306 | 310 |
| Working Capital Days | 275 | 186 | 159 | 177 | 163 | 153 | 166 | 193 |
| ROCE % | 27% | 25% | 32% | 21% | 26% | 28% | 28% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| DSP Small Cap Fund | 920,427 | 0.77 | 130.48 | 751,879 | 2025-12-15 03:14:25 | 22.42% |
| SBI Healthcare Opportunities Fund | 720,000 | 2.47 | 102.07 | N/A | N/A | N/A |
| HSBC Small Cap Fund | 591,730 | 0.52 | 83.88 | 853,962 | 2025-12-15 03:14:25 | -30.71% |
| DSP Healthcare Fund | 489,774 | 2.18 | 69.43 | N/A | N/A | N/A |
| Invesco India Smallcap Fund | 330,193 | 0.52 | 46.81 | 257,629 | 2025-10-15 02:40:18 | 28.17% |
| Invesco India Multicap Fund | 282,437 | 0.94 | 40.04 | 226,042 | 2025-11-03 03:32:39 | 24.95% |
| Invesco India Flexi Cap Fund | 178,114 | 0.54 | 25.25 | N/A | N/A | N/A |
| Edelweiss Small Cap Fund | 145,577 | 0.39 | 20.64 | 264,705 | 2025-10-15 02:40:18 | -45% |
| Nippon India Pharma Fund | 111,738 | 0.19 | 15.84 | N/A | N/A | N/A |
| Union Small Cap Fund | 70,000 | 0.56 | 9.92 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 10.00 |
| Basic EPS (Rs.) | 35.52 | 29.45 | 22.95 | 16.72 |
| Diluted EPS (Rs.) | 35.52 | 29.45 | 22.95 | 16.72 |
| Cash EPS (Rs.) | 40.85 | 34.25 | 27.93 | 240.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 173.27 | 145.93 | 123.31 | 1159.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 173.27 | 145.93 | 123.31 | 1159.99 |
| Revenue From Operations / Share (Rs.) | 114.71 | 97.21 | 81.55 | 749.62 |
| PBDIT / Share (Rs.) | 52.65 | 44.48 | 36.19 | 311.96 |
| PBIT / Share (Rs.) | 47.45 | 39.36 | 31.02 | 259.33 |
| PBT / Share (Rs.) | 47.40 | 39.11 | 30.59 | 253.57 |
| Net Profit / Share (Rs.) | 35.65 | 29.13 | 22.76 | 187.76 |
| NP After MI And SOA / Share (Rs.) | 35.52 | 29.45 | 22.95 | 183.93 |
| PBDIT Margin (%) | 45.89 | 45.75 | 44.37 | 41.61 |
| PBIT Margin (%) | 41.36 | 40.48 | 38.04 | 34.59 |
| PBT Margin (%) | 41.31 | 40.23 | 37.51 | 33.82 |
| Net Profit Margin (%) | 31.07 | 29.96 | 27.91 | 25.04 |
| NP After MI And SOA Margin (%) | 30.96 | 30.29 | 28.14 | 24.53 |
| Return on Networth / Equity (%) | 20.50 | 20.18 | 18.61 | 15.85 |
| Return on Capital Employeed (%) | 26.82 | 26.41 | 24.54 | 21.30 |
| Return On Assets (%) | 18.26 | 18.11 | 15.85 | 13.32 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.02 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.02 | 0.05 |
| Asset Turnover Ratio (%) | 0.64 | 0.63 | 0.60 | 0.00 |
| Current Ratio (X) | 6.17 | 6.30 | 3.79 | 4.08 |
| Quick Ratio (X) | 4.87 | 4.84 | 2.69 | 2.82 |
| Inventory Turnover Ratio (X) | 5.36 | 0.87 | 0.82 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 24.63 | 23.19 | 22.31 | 40.31 |
| Dividend Payout Ratio (CP) (%) | 21.48 | 19.75 | 18.21 | 31.34 |
| Earning Retention Ratio (%) | 75.37 | 76.81 | 77.69 | 59.69 |
| Cash Earning Retention Ratio (%) | 78.52 | 80.25 | 81.79 | 68.66 |
| Interest Coverage Ratio (X) | 1040.58 | 182.35 | 83.94 | 54.11 |
| Interest Coverage Ratio (Post Tax) (X) | 705.64 | 120.41 | 53.80 | 33.56 |
| Enterprise Value (Cr.) | 17536.50 | 15881.24 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 14.61 | 15.62 | 0.00 | 0.00 |
| EV / EBITDA (X) | 31.84 | 34.13 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 14.61 | 15.66 | 0.00 | 0.00 |
| Retention Ratios (%) | 75.36 | 76.80 | 77.68 | 59.68 |
| Price / BV (X) | 9.67 | 10.43 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 14.61 | 15.66 | 0.00 | 0.00 |
| EarningsYield | 0.02 | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Concord Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
- For Diluted EPS (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
- For Cash EPS (Rs.), as of Mar 25, the value is 40.85. This value is within the healthy range. It has increased from 34.25 (Mar 24) to 40.85, marking an increase of 6.60.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 173.27. It has increased from 145.93 (Mar 24) to 173.27, marking an increase of 27.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 173.27. It has increased from 145.93 (Mar 24) to 173.27, marking an increase of 27.34.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 114.71. It has increased from 97.21 (Mar 24) to 114.71, marking an increase of 17.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 52.65. This value is within the healthy range. It has increased from 44.48 (Mar 24) to 52.65, marking an increase of 8.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 47.45. This value is within the healthy range. It has increased from 39.36 (Mar 24) to 47.45, marking an increase of 8.09.
- For PBT / Share (Rs.), as of Mar 25, the value is 47.40. This value is within the healthy range. It has increased from 39.11 (Mar 24) to 47.40, marking an increase of 8.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 35.65. This value is within the healthy range. It has increased from 29.13 (Mar 24) to 35.65, marking an increase of 6.52.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 35.52. This value is within the healthy range. It has increased from 29.45 (Mar 24) to 35.52, marking an increase of 6.07.
- For PBDIT Margin (%), as of Mar 25, the value is 45.89. This value is within the healthy range. It has increased from 45.75 (Mar 24) to 45.89, marking an increase of 0.14.
- For PBIT Margin (%), as of Mar 25, the value is 41.36. This value exceeds the healthy maximum of 20. It has increased from 40.48 (Mar 24) to 41.36, marking an increase of 0.88.
- For PBT Margin (%), as of Mar 25, the value is 41.31. This value is within the healthy range. It has increased from 40.23 (Mar 24) to 41.31, marking an increase of 1.08.
- For Net Profit Margin (%), as of Mar 25, the value is 31.07. This value exceeds the healthy maximum of 10. It has increased from 29.96 (Mar 24) to 31.07, marking an increase of 1.11.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 30.96. This value exceeds the healthy maximum of 20. It has increased from 30.29 (Mar 24) to 30.96, marking an increase of 0.67.
- For Return on Networth / Equity (%), as of Mar 25, the value is 20.50. This value is within the healthy range. It has increased from 20.18 (Mar 24) to 20.50, marking an increase of 0.32.
- For Return on Capital Employeed (%), as of Mar 25, the value is 26.82. This value is within the healthy range. It has increased from 26.41 (Mar 24) to 26.82, marking an increase of 0.41.
- For Return On Assets (%), as of Mar 25, the value is 18.26. This value is within the healthy range. It has increased from 18.11 (Mar 24) to 18.26, marking an increase of 0.15.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.63 (Mar 24) to 0.64, marking an increase of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 6.17. This value exceeds the healthy maximum of 3. It has decreased from 6.30 (Mar 24) to 6.17, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 4.87. This value exceeds the healthy maximum of 2. It has increased from 4.84 (Mar 24) to 4.87, marking an increase of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.36. This value is within the healthy range. It has increased from 0.87 (Mar 24) to 5.36, marking an increase of 4.49.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.19 (Mar 24) to 24.63, marking an increase of 1.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 21.48. This value is within the healthy range. It has increased from 19.75 (Mar 24) to 21.48, marking an increase of 1.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is 75.37. This value exceeds the healthy maximum of 70. It has decreased from 76.81 (Mar 24) to 75.37, marking a decrease of 1.44.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 78.52. This value exceeds the healthy maximum of 70. It has decreased from 80.25 (Mar 24) to 78.52, marking a decrease of 1.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,040.58. This value is within the healthy range. It has increased from 182.35 (Mar 24) to 1,040.58, marking an increase of 858.23.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 705.64. This value is within the healthy range. It has increased from 120.41 (Mar 24) to 705.64, marking an increase of 585.23.
- For Enterprise Value (Cr.), as of Mar 25, the value is 17,536.50. It has increased from 15,881.24 (Mar 24) to 17,536.50, marking an increase of 1,655.26.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.62 (Mar 24) to 14.61, marking a decrease of 1.01.
- For EV / EBITDA (X), as of Mar 25, the value is 31.84. This value exceeds the healthy maximum of 15. It has decreased from 34.13 (Mar 24) to 31.84, marking a decrease of 2.29.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.66 (Mar 24) to 14.61, marking a decrease of 1.05.
- For Retention Ratios (%), as of Mar 25, the value is 75.36. This value exceeds the healthy maximum of 70. It has decreased from 76.80 (Mar 24) to 75.36, marking a decrease of 1.44.
- For Price / BV (X), as of Mar 25, the value is 9.67. This value exceeds the healthy maximum of 3. It has decreased from 10.43 (Mar 24) to 9.67, marking a decrease of 0.76.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 14.61. This value exceeds the healthy maximum of 3. It has decreased from 15.66 (Mar 24) to 14.61, marking a decrease of 1.05.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Concord Biotech Ltd:
- Net Profit Margin: 31.07%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 26.82% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 20.5% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 705.64
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 4.87
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 43.6 (Industry average Stock P/E: 52.7)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 31.07%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 1482-1486, Trasad Road, Ahmedabad Gujarat 382225 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sudhir Vaid | Chairman & Managing Director |
| Mr. Ankur Vaid | Joint Managing Director & CEO |
| Mr. Ravi Kapoor | Non Executive Director |
| Mr. Rajiv Ambrish Agarwal | Non Executive Director |
| Mrs. Bharti Khanna | Independent Director |
| Mr. Amitabh Thakore | Independent Director |
| Mr. Arvind Agarwal | Independent Director |
| Mr. Jayaram Easwaran | Independent Director |
| Mr. Mandayam Chakravarthy Sriraman | Independent Director |
FAQ
What is the intrinsic value of Concord Biotech Ltd?
Concord Biotech Ltd's intrinsic value (as of 28 December 2025) is 1309.18 which is 2.30% lower the current market price of 1,340.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 14,019 Cr. market cap, FY2025-2026 high/low of 2,452/1,315, reserves of ₹1,815 Cr, and liabilities of 2,021 Cr.
What is the Market Cap of Concord Biotech Ltd?
The Market Cap of Concord Biotech Ltd is 14,019 Cr..
What is the current Stock Price of Concord Biotech Ltd as on 28 December 2025?
The current stock price of Concord Biotech Ltd as on 28 December 2025 is 1,340.
What is the High / Low of Concord Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Concord Biotech Ltd stocks is 2,452/1,315.
What is the Stock P/E of Concord Biotech Ltd?
The Stock P/E of Concord Biotech Ltd is 43.6.
What is the Book Value of Concord Biotech Ltd?
The Book Value of Concord Biotech Ltd is 174.
What is the Dividend Yield of Concord Biotech Ltd?
The Dividend Yield of Concord Biotech Ltd is 0.80 %.
What is the ROCE of Concord Biotech Ltd?
The ROCE of Concord Biotech Ltd is 28.4 %.
What is the ROE of Concord Biotech Ltd?
The ROE of Concord Biotech Ltd is 21.4 %.
What is the Face Value of Concord Biotech Ltd?
The Face Value of Concord Biotech Ltd is 1.00.